{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T17:26:58Z","timestamp":1769880418740,"version":"3.49.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s11926-022-01078-2","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:03:03Z","timestamp":1657152183000},"page":"259-267","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Interstitial Lung Disease in ANCA-Associated Vasculitis: Pathogenic Considerations and Impact for Patients\u2019 Outcomes"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6667-142X","authenticated-orcid":false,"given":"Kelly","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8123-923X","authenticated-orcid":false,"given":"Jolene H.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6287-9549","authenticated-orcid":false,"given":"Christian","family":"Pagnoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,7]]},"reference":[{"key":"1078_CR1","first-page":"1","volume":"2013","author":"JC Jennette","year":"2012","unstructured":"Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2012;2013:1\u201311.","journal-title":"Arthritis Rheum"},{"issue":"19","key":"1078_CR2","doi-asserted-by":"publisher","first-page":"7319","DOI":"10.3390\/ijms21197319","volume":"21","author":"A Kronbichler","year":"2020","unstructured":"Kronbichler A, Lee KH, Denicolo S, Choi D, Lee H, Ahn D, et al. Immunopathogenesis of ANCA-associated vasculitis. Int J Mol Sci. 2020;21(19):7319.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1078_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","volume":"6","author":"AR Kitching","year":"2020","unstructured":"Kitching AR, Anders H-J, Basu N, Brouwer E, Gordon J, Jayne DR, et al. ANCA-associated vasculitis. Nat Rev Dis Prim. 2020;6(1):71.","journal-title":"Nat Rev Dis Prim"},{"key":"1078_CR4","unstructured":"Thompson A. Tarascon pocket rheumatologica. Fourth. Sudbury, Massachusetts: Jones and Bartlett Publishers, 2010."},{"issue":"1","key":"1078_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1053\/j.ajkd.2019.04.031","volume":"75","author":"D Geetha","year":"2020","unstructured":"Geetha D, Jefferson JA. ANCA-associated vasculitis: core curriculum 2020. Am J Kidney Dis. 2020;75(1):124\u201337.","journal-title":"Am J Kidney Dis"},{"key":"1078_CR6","doi-asserted-by":"crossref","unstructured":"Villiger PM, Guillevin L. Microscopic polyangiitis: clinical presentation.\u00a0Autoimmun Rev.\u00a02010;9(12);812\u20139.","DOI":"10.1016\/j.autrev.2010.07.009"},{"key":"1078_CR7","doi-asserted-by":"crossref","unstructured":"Sacoto G, Boukhlal S, Specks U, Flores-Su\u00e1rez LF, Cornec D. Lung involvement in ANCA-associated vasculitis.\u00a0Presse Med. 2020;49( 3);104039.","DOI":"10.1016\/j.lpm.2020.104039"},{"key":"1078_CR8","doi-asserted-by":"crossref","unstructured":"Watts RA, Al-Taiar A, Scott DGI, Macgregor AJ. Prevalence and incidence of Wegener\u2019s granulomatosis in the UK general practice research database.\u00a0Arthritis Rheum. 2009;61(10):1412\u20136","DOI":"10.1002\/art.24544"},{"key":"1078_CR9","doi-asserted-by":"crossref","unstructured":"Mohammad AJ, Jacobsson LTH, Westman KWA, Sturfelt G, Segelmark M. Incidence and survival rates in Wegener\u2019s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa.\u00a0Rheumatol (Oxford). 2009;48(12):1560\u20135.","DOI":"10.1093\/rheumatology\/kep304"},{"key":"1078_CR10","doi-asserted-by":"crossref","unstructured":"Berti A, Cornec D, Crowson CS, Specks U, Matteson EL. The epidemiology of antineutrophil cytoplasmic autoantibody-associated vasculitis in Olmsted County, Minnesota. Arthritis Rheum. 2017;69(12):2338\u201350.","DOI":"10.1002\/art.40313"},{"key":"1078_CR11","doi-asserted-by":"crossref","unstructured":"\u2022 Fisher JH, Kolb M, Algamdi M, Morisset J, Johannson KA, Shapera S, et al. Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis. BMC Pulm Med. 2019;19(1):223. A large cohort study, that helped determine the frequency of ANCA positivity in ILD in Canada.","DOI":"10.1186\/s12890-019-0986-4"},{"issue":"10","key":"1078_CR12","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1007\/s00296-011-2079-4","volume":"32","author":"JK Ahn","year":"2012","unstructured":"Ahn JK, Hwang J-W, Lee J, Jeon CH, Cha H-S, Koh E-M. Clinical features and outcome of microscopic polyangiitis under a new consensus algorithm of ANCA-associated vasculitides in Korea. Rheumatol Int. 2012;32(10):2979\u201386.","journal-title":"Rheumatol Int"},{"issue":"162","key":"1078_CR13","doi-asserted-by":"publisher","first-page":"210123","DOI":"10.1183\/16000617.0123-2021","volume":"30","author":"S Kadura","year":"2021","unstructured":"\u2022 Kadura S, Raghu G. Antineutrophil cytoplasmic antibody-associated interstitial lung disease: a review. Eur Respir Rev. 2021;30(162):210123. A great review on AAV-ILD.","journal-title":"Eur Respir Rev"},{"key":"1078_CR14","doi-asserted-by":"crossref","unstructured":"Nada AK, Torres VE, Ryu JH, Lie JT, Holley KE. Pulmonary fibrosis as an unusual clinical manifestation of a pulmonary-renal vasculitis in elderly patients. Mayo Clin Proc 1990;65(6):847\u201356.","DOI":"10.1016\/S0025-6196(12)62575-0"},{"key":"1078_CR15","doi-asserted-by":"crossref","unstructured":"Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, et al. An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46(4):976\u201387.","DOI":"10.1183\/13993003.00150-2015"},{"key":"1078_CR16","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Sun X, Peng M, Zhang T, Li Z, Song L, Li M, et al. Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody. BMC Pulm Med. 2021;21(1):88. A great series and review on AAV-ILD.","DOI":"10.1186\/s12890-021-01451-4"},{"issue":"3","key":"1078_CR17","first-page":"133","volume":"1","author":"KA Johannson","year":"2017","unstructured":"Johannson KA, Kolb M, Fell CD, Assayag D, Fisher J, Churg A, et al. Evaluation of patients with fibrotic interstitial lung disease: a Canadian Thoracic Society position statement. Can J Respir Crit Care Sleep Med. 2017;1(3):133\u201341.","journal-title":"Can J Respir Crit Care Sleep Med"},{"key":"1078_CR18","doi-asserted-by":"crossref","unstructured":"Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44\u2013e68.","DOI":"10.1164\/rccm.201807-1255ST"},{"key":"1078_CR19","doi-asserted-by":"crossref","unstructured":"Ando M, Miyazaki E, Ishii T, Mukai Y, Yamasue M, Fujisaki H et al. Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis. Respir Med. 2013;107(4):608\u201315.","DOI":"10.1016\/j.rmed.2013.01.006"},{"issue":"1","key":"1078_CR20","first-page":"1","volume":"2","author":"N Kagiyama","year":"2015","unstructured":"Kagiyama N, Takayanagi N, Kanauchi T, Ishiguro T, Yanagisawa T, Sugita Y. Antineutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis. BMJ Open Respir Res. 2015;2(1):1\u20139.","journal-title":"BMJ Open Respir Res"},{"issue":"2","key":"1078_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00408-016-9851-x","volume":"194","author":"H Hozumi","year":"2016","unstructured":"Hozumi H, Enomoto N, Oyama Y, Kono M, Fujisawa T, Inui N, et al. Clinical implication of proteinase-3-antineutrophil cytoplasmic antibody in patients with idiopathic interstitial pneumonias. Lung. 2016;194(2):235\u201342.","journal-title":"Lung"},{"key":"1078_CR22","doi-asserted-by":"crossref","unstructured":"Hozumi H, Oyama Y, Yasui H, Suzuki Y, Kono M, Karayama M et al. Clinical significance of myeloperoxidase-antineutrophil cytoplasmic antibody in idiopathic interstitial pneumonias. PLoS One. 2018;13(6):e019965.","DOI":"10.1371\/journal.pone.0199659"},{"issue":"4","key":"1078_CR23","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.chest.2019.05.014","volume":"156","author":"GY Liu","year":"2019","unstructured":"\u2022\u2022 Liu GY, Ventura IB, Achtar-Zadeh N, Elicker BM, Jones KD, Wolters PJ, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in North American patients with idiopathic pulmonary fibrosis. Chest. 2019;156(4):715\u201323. A large cohort study, that helped determine the frequency of ANCA positivity in ILD in North America.","journal-title":"Chest"},{"key":"1078_CR24","doi-asserted-by":"crossref","unstructured":"\u2022 Fidler LM, Kandel S, Fisher JH, Mittoo S, Shapera S. Utility of anti-neutrophil cytoplasmic antibody screening in idiopathic interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis. 2021;38(2):e2021015. A study on the utility of ANCA testing in ILD.","DOI":"10.1164\/ajrccm-conference.2020.201.1_MeetingAbstracts.A3367"},{"key":"1078_CR25","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Maillet T, Goletto T, Beltramo G, Dupuy H, Jouneau S, Borie R et al. Usual interstitial pneumonia in ANCA-associated vasculitis: a poor prognostic factor. J Autoimmun. 2020;106:102338. A series of AAV-ILD and its prognostic implications.","DOI":"10.1016\/j.jaut.2019.102338"},{"issue":"1","key":"1078_CR26","first-page":"37","volume":"37","author":"P Wurmann","year":"2020","unstructured":"Wurmann P, Sabugo F, Elgueta F, Mac-Namara M, Vergara K, Vargas D, et al. Interstitial lung disease and microscopic polyangiitis in chilean patients. Sarcoidosis Vasc Diffuse Lung Dis. 2020;37(1):37\u201342.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"1078_CR27","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Watanabe T, Minezawa T, Hasegawa M, Goto Y, Okamura T, Sakakibara Y et al. Prognosis of pulmonary fibrosis presenting with a usual interstitial pneumonia pattern on computed tomography in patients with myeloperoxidase anti-neutrophil cytoplasmic antibody-related nephritis: a retrospective single-center study. BMC Pulm Med. 2019;19(1):194. Another series of AAV-ILD and its prognostic implications.","DOI":"10.1186\/s12890-019-0969-5"},{"issue":"3","key":"1078_CR28","first-page":"195","volume":"36","author":"M Baqir","year":"2019","unstructured":"\u2022\u2022 Baqir M, Yi EE, Colby TV, Cox CW, Ryu JH, Specks U. Radiologic and pathologic characteristics of myeloperoxidase-antineutrophil cytoplasmic antibody-associated interstitial lung disease: a retrospective analysis. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG. 2019;36(3):195\u2013201. Another series of AAV-ILD and its radiological features.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG"},{"key":"1078_CR29","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Kwon M, Lee AS, Mira-Avendano I, Rojas CA, Grage R, Abril A. Interstitial lung disease in antineutrophil cytoplasmic antibody\u2013associated vasculitis patients. JCR: J Clin Rheumatol [Internet]. 2021 Dec;27(8):324\u201330. Available from: https:\/\/journals.lww.com\/https:\/\/doi.org\/10.1097\/RHU.0000000000001357. Another series of AAV-ILD.","DOI":"10.1097\/RHU.0000000000001357"},{"key":"1078_CR30","doi-asserted-by":"crossref","unstructured":"Birnbaum J, Danoff S, Askin FB, Stone JH. Microscopic polyangiitis presenting as a \u201cpulmonary-muscle\u201d syndrome: Is subclinical alveolar hemorrhage the mechanism of pulmonary fibrosis? Arthritis Rheum. 2007;56(6).","DOI":"10.1002\/art.22633"},{"issue":"10","key":"1078_CR31","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.rmed.2008.04.023","volume":"102","author":"G Foulon","year":"2008","unstructured":"Foulon G, Delaval P, Valeyre D, Wallaert B, Debray MP, Brauner M, et al. ANCA-associated lung fibrosis: analysis of 17 patients. Respir Med. 2008;102(10):1392\u20138.","journal-title":"Respir Med"},{"key":"1078_CR32","doi-asserted-by":"crossref","unstructured":"Tanaka T, Otani K, Egashira R, Kashima Y, Taniguchi H, Kondoh Y, et al. Interstitial pneumonia associated with MPO-ANCA: clinicopathological features of nine patients. Respir Med. 2012;106(12):1765\u201370.","DOI":"10.1016\/j.rmed.2012.08.024"},{"key":"1078_CR33","doi-asserted-by":"crossref","unstructured":"Foucher P, Heeringa P, Petersen AH, Huitema MG, Brouwer E, Cohen Tervaert JW et al. Antimyeloperoxidase-associated lung disease. Am J Respir Crit Care Med. 1999;160(3).","DOI":"10.1164\/ajrccm.160.3.9807139"},{"key":"1078_CR34","doi-asserted-by":"crossref","unstructured":"Guilpain P, Chereau C, Goulvestre C, Servettaz A, Montani D, Tamas N et al. The oxidation induced by antimyeloperoxidase antibodies triggers fibrosis in microscopic polyangiitis. Eur Respir J. 2011;37(6).","DOI":"10.1183\/09031936.00148409"},{"key":"1078_CR35","doi-asserted-by":"crossref","unstructured":"Kessenbrock K, Krumbholz M, Sch\u00f6nermarck U, Back W, Gross WL, Werb Z et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009;15(6):623\u20135.","DOI":"10.1038\/nm.1959"},{"key":"1078_CR36","doi-asserted-by":"crossref","unstructured":"Yoshida M, Yamada M, Sudo Y, Kojima T, Tomiyasu T, Yoshikawa N et al. Myeloperoxidase anti\u2010neutrophil cytoplasmic antibody affinity is associated with the formation of neutrophil extracellular traps in the kidney and vasculitis activity in myeloperoxidase anti\u2010neutrophil cytoplasmic antibody\u2010associated microscopic polyangiitis.\u00a0Nephrology (Carlton). 2016;21(7):624\u20139.","DOI":"10.1111\/nep.12736"},{"key":"1078_CR37","doi-asserted-by":"crossref","unstructured":"Sangaletti S, Tripodo C, Chiodoni C, Guarnotta C, Cappetti B, Casalini P et al. Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. Blood. 2012;120(15):3007\u201318.","DOI":"10.1182\/blood-2012-03-416156"},{"issue":"8","key":"1078_CR38","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/annrheumdis-2018-214263","volume":"78","author":"N Namba","year":"2019","unstructured":"\u2022 Namba N, Kawasaki A, Sada K, Hirano F, Kobayashi S, Yamada H, et al. Association of MUC5B promoter polymorphism with interstitial lung disease in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis. Ann Rheum Dis. 2019;78(8):1144\u20136. A genetic study in AAV-ILD, suggesting some occasional genetic predisposing alleles.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1078_CR39","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s13075-020-02347-0","volume":"22","author":"A Kawasaki","year":"2020","unstructured":"\u2022 Kawasaki A, Namba N, Sada K, Hirano F, Kobayashi S, Nagasaka K, et al. Association of TERT and DSP variants with microscopic polyangiitis and myeloperoxidase-ANCA positive vasculitis in a Japanese population: a genetic association study. Arthritis Res Ther. 2020;22(1):246. Another genetic study in AAV-ILD, suggesting some occasional genetic predisposing alleles.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"1078_CR40","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1183\/09031936.97.10122738","volume":"10","author":"A Schnabel","year":"1997","unstructured":"Schnabel A, Holl-Ulrich K, Dalhoff K, Reuter M, Gross WL. Efficacy of transbronchial biopsy in pulmonary vaculitides. Eur Respir J. 1997;10(12):2738\u201343.","journal-title":"Eur Respir J"},{"key":"1078_CR41","doi-asserted-by":"crossref","unstructured":"Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010; 363.","DOI":"10.1056\/NEJMoa0909905"},{"issue":"7","key":"1078_CR42","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne DRW, Merkel PA, Schall TJ, Bekker P. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384(7):599\u2013609.","journal-title":"N Engl J Med"},{"issue":"7","key":"1078_CR43","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","volume":"382","author":"M Walsh","year":"2020","unstructured":"Walsh M, Merkel PA, Peh C-A, Szpirt WM, Pu\u00e9chal X, Fujimoto S, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382(7):622\u201331.","journal-title":"N Engl J Med"},{"key":"1078_CR44","doi-asserted-by":"crossref","unstructured":"Pagnoux C, Mahr A, Hamidou MA, Boffa J-J, Ruivard M, Ducroix J-P et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359(26).","DOI":"10.1056\/NEJMoa0802311"},{"issue":"19","key":"1078_CR45","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin L, Pagnoux C, Karras A, Khouatra C, Auma\u00eetre O, Cohen P, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771\u201380.","journal-title":"N Engl J Med"},{"issue":"3","key":"1078_CR46","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/ard.2008.096131","volume":"68","author":"B Hervier","year":"2009","unstructured":"Hervier B, Pagnoux C, Agard C, Haroche J, Amoura Z, Guillevin L, et al. Pulmonary fibrosis associated with ANCA-positive vasculitides. Retrospective study of 12 cases and review of the literature. Ann Rheum Dis. 2009;68(3):404\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"24","key":"1078_CR47","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/MD.0000000000000217","volume":"93","author":"C Comarmond","year":"2014","unstructured":"Comarmond C, Crestani B, Tazi A, Hervier B, Adam-Marchand S, Nunes H, et al. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis. Medicine. 2014;93(24):340\u20139.","journal-title":"Medicine"},{"issue":"18","key":"1078_CR48","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"\u2022\u2022 Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718\u201327. A major trial in ILD on nintedanib, an antifibrotic agent.","journal-title":"N Engl J Med"},{"key":"1078_CR49","unstructured":"\u2022 Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9(5):476\u201386. Another trial in ILD on pirfenidone, an antifibrotic agent."},{"key":"1078_CR50","doi-asserted-by":"crossref","unstructured":"\u2022 Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020;8(2):147\u201357. Another trial in ILD on pirfenidone, an antifibrotic agent.","DOI":"10.1016\/S2213-2600(19)30341-8"},{"issue":"26","key":"1078_CR51","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"\u2022 Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis\u2013associated interstitial lung disease. N Engl J Med. 2019;380(26):2518\u201328. Another major trial in ILD on nintedanib, an antifibrotic agent.","journal-title":"N Engl J Med"},{"key":"1078_CR52","doi-asserted-by":"crossref","unstructured":"Luppi F, Sebastiani M, Salvarani C, Bendstrup E, Manfredi A. Acute exacerbation of interstitial lung disease associated with rheumatic disease. Nat Rev Rheumatol.\u00a0 2022;18(2):85\u201396.","DOI":"10.1038\/s41584-021-00721-z"},{"issue":"3","key":"1078_CR53","first-page":"147","volume":"4","author":"JH Fisher","year":"2020","unstructured":"\u2022 Fisher JH, Johannson KA, Assayag D, Morisset J, de Boer K, Manganas H, et al. Long-term monitoring of patients with fibrotic interstitial lung disease: a Canadian Thoracic Society Position Statement. Can J Respir Crit Care Sleep Med. 2020;4(3):147\u201355. A review and guidance on how to monitor ILD patients.","journal-title":"Can J Respir Crit Care Sleep Med"},{"issue":"6","key":"1078_CR54","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788\u2013824.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-022-01078-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-022-01078-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-022-01078-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T10:40:03Z","timestamp":1658486403000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-022-01078-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1078"],"URL":"https:\/\/doi.org\/10.1007\/s11926-022-01078-2","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,7]]},"assertion":[{"value":"19 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Sun reports grants from the Canadian Pulmonary Fibrosis Foundation. Dr. Fisher reports\u00a0grants from the Canadian Pulmonary Fibrosis Foundation, and personal fees from Boehringer-\u00a0Ingelheim and AstraZeneca, outside the submitted work. Dr. Pagnoux reports grants and\u00a0honoraria (consultancy boards) or speaker fees from Roche, GSK, Pfizer, TEVA, and personal\u00a0fees (consultancy boards or speaker fees) from InflaRx, Otsuka, Chemo Centryx, AstraZeneca, and Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All reported studies\/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}